These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35226358)

  • 1. Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
    Mori A; Onozawa M; Tsukamoto S; Ishio T; Yokoyama E; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T
    Br J Haematol; 2022 Jun; 197(6):691-696. PubMed ID: 35226358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Helfgott DC; Racine-Brzostek S; Short KJ; Zhao Z; Christos P; Nino I; Niu T; Contreras J; Ritchie EK; Desai P; Samuel M; Roboz GJ
    Leuk Lymphoma; 2023 Mar; 64(3):662-670. PubMed ID: 36282213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia.
    Mori A; Onozawa M; Kobayashi M; Tsukamoto S; Senjo H; Ishio T; Yokoyama E; Izumiyama K; Saito M; Muraki H; Morioka M; Teshima T; Kondo T
    Br J Haematol; 2023 Mar; 200(6):717-721. PubMed ID: 36442510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders].
    Hagihara M; Sugi T; Uchida T; Ohara S; Imai Y; Inoue M; Mitamura K
    Rinsho Ketsueki; 2022; 63(4):247-253. PubMed ID: 35491212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination for SARS-CoV-2 in Hematological Patients.
    Riccardi N; Falcone M; Yahav D
    Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
    Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
    Front Immunol; 2022; 13():845882. PubMed ID: 35401504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western Greece.
    Parthymou A; Habeos EE; Habeos GI; Deligakis A; Livieratos E; Marangos M; Chartoumpekis DV
    BMJ Open; 2022 May; 12(5):e057084. PubMed ID: 35589363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
    Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
    Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.
    Chan WY; Zhu C; Sanchez E; Gupta R; Fielding AK; Khwaja A; Payne EM; O'Nions J
    Br J Haematol; 2022 Aug; 198(3):478-481. PubMed ID: 35536283
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignancies.
    Ikeda D; Terao T; Fukumoto A; Uesugi Y; Tabata R; Kuzume A; Tsushima T; Miura D; Narita K; Takeuchi M; Yamashita T; Takamatsu H; Matsue K
    Br J Haematol; 2023 Mar; 200(5):568-572. PubMed ID: 36345272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies.
    Bergamaschi C; Pagoni M; Rosati M; Angel M; Tzannou I; Vlachou M; Darmani I; Ullah A; Bear J; Devasundaram S; Burns R; Baltadakis I; Gigantes S; Dimopoulos MA; Pavlakis GN; Terpos E; Felber BK
    Front Immunol; 2022; 13():899972. PubMed ID: 35693807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
    Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L
    PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.